PROCEPT BioRobotics (NASDAQ:PRCT) Has Debt But No Earnings; Should You Worry?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious

Simply Wall StMay 21 12:07

PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference

SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solu

PROCEPT BioRobotics May 12 23:00

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Amgen (AMGN) and Elevation Oncology (ELEV)

TipRanksMay 7 23:10

PROCEPT BioRobotics Is Maintained at Buy by TD Cowen

PROCEPT BioRobotics Is Maintained at Buy by TD Cowen

Dow JonesMay 6 11:11

PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen

PROCEPT BioRobotics Price Target Raised to $75.00/Share From $65.00 by TD Cowen

Dow JonesMay 6 11:11

Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.

Piper Sandler: Maintaining the PROCEPT BioRobotics (PRCT.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $67.00 to $75.00.

Zhitong FinanceMay 6 08:01